$ORIC (L) As long as we're highlighting the importance of leadership:
June 14, 2023, 2:53 p.m.
$PDSB (NP) Lot of misleading commentary out there today ASCO showed 9 responses in 34 evaluable patients Since then, more patients have been enrolled to achieve 14 total responses (complete or partial) While the company does not specify how many additional patients were…
June 14, 2023, 2:15 p.m.
$XBI $IBB Undervalued commercial-stage ideas without "hair" on them (overhangs) are hard to find. Too many either: #1 Waiting for confirmatory data (ie. $AMLX, $TVTX) #2 Need to strengthen balance sheet & burning too much cash (ie. $ARQT $MRTX) #3 Binary catalyst (ie. $URGN…
June 12, 2023, 11:58 p.m.
$ADCT (NP) Mental exercise- my stab at a possible thesis Devil's advocate (reasons not to pull trigger): -Still not enough evidence that the story is improving -DLBCL= very crowded market with bispecifics (e.g. glofitamab) and CAR-T set to take the most share -Dragging its…
June 12, 2023, 11:15 p.m.
@sentivcapital @bradloncar @BiotechTVHQ Love that Brad asks the tough questions, ie new high dose Eylea (every 4 months) affecting landscape & value proposition for $OCUL
June 12, 2023, 5:10 p.m.
$KDNY (NP) Congrats to longs on $3.2B $NVS buyout Hindsight is always 20/20 as they say, but the elements we look for were there Clinical momentum for atrasentan= 2H 23 pivotal readout in IgAN & update on basket cohorts. Approval decision 2024 BION-1301 APRIL antibody for…
June 12, 2023, 12:57 p.m.
$DAWN (NP) Weekly chart looks heavy to my eyes with potential gap down below offering price to single-digits I think most people (even critics) realize Tovo results in relapsed pLGG were best case scenario But key overhangs include: -Whether "totality of data" will be…
June 11, 2023, 9:41 p.m.
Case in point for Core (commercial-stage) Portfolio My rough patch in 2021-2022 was only partly attributable to biotech bear market $XBI $IBB At least half of poor performance due to my unforced errors, failure to control my emotions, overtrading & poor selection criteria…
June 11, 2023, 3:35 p.m.
Case in point for Core (commercial-stage) Portfolio My rough patch in 2021-2022 was only partly attributable to biotech bear market $XBI $IBB At least half of poor performance due to my unforced errors, failure to control my emotions, overtrading & poor selection criteria…
June 11, 2023, 3:26 p.m.
$URGN (NP) #JefferiesHealthcare was a worthwhile listen: UGN-102 phase 3 readout end of July/early August. Setting the bar for expectations at 50% CR rate. Caveat for ENVISION study that we won't see durability until Q1 2024 with approval by early 2025. Pricing here will be…
June 10, 2023, 9:18 p.m.
$URGN (NP) #JefferiesHealthcare was a worthwhile listen: UGN-102 phase 3 readout end of July/early August. Setting the bar for expectations at 50% CR rate. Caveat for ENVISION study that we won't see durability until Q1 2024 with approval by early 2025. Pricing here will be…
June 10, 2023, 9:17 p.m.
$URGN (NP) #JefferiesHealthcare was a worthwhile listen: UGN-102 phase 3 readout end of July/early August. Setting the bar for expectations at 50% CR rate. Caveat for ENVISION study that we won't see durability until Q1 2024 with approval by early 2025. Pricing here will be…
June 10, 2023, 9:13 p.m.
$XBI $IBB Some of the most helpful people in my feed are those who criticize my stock holdings & tear apart my picks Who poke holes in my thesis and show me where I could be wrong Case in point this year, such folks helped me exit $RLAY $RAIN $ACRS before negative binary…
June 10, 2023, 7:21 p.m.
$MRUS (L) $900M EV If I didn't know any better, this looks like a buyout formation (steady upward climb from May lows) Peto (EGFR Lgr5 bispecific) is the main attraction with ORR actually going up in each subsequent update (opposite of what one would expect) 37% ORR in HNSCC…
June 10, 2023, 3:18 p.m.
$XBI $IBB TA into the weekend: $FDMT- nice delayed reaction to CF data as market digests the news & its broader implications $TELA- acting like it's ready to break out into mid-teens (my largest commercial-stage holding, fwiw) $URGN firming up ahead of pivotal mid-year…
June 9, 2023, 7:57 p.m.
$AGEN (L) One reason it's running is that CEO confirmed they intend to pursue accelerated approval pathway for CRC 20,000+ addressable patients (refractory, non-MSI-H/dMMR, no active liver mets) January 2024 primary completion date with regulatory filing later in the year
June 8, 2023, 10:02 p.m.
$XBI $IBB Humbling aspect of investing in biotech is when we get it wrong (ie. share price cut in half on data drop, painful dilution at lows, poor launch metrics point to reduced market opportunity) Just as it's quite painful when thesis fails to pan out, lately I'm reminded…
June 8, 2023, 9:49 p.m.
$SGMO (NP) -$20M EV I do wonder when this one will get its due When the market will value it as a viable enterprise instead of a science project Fabry dosed 20 patients & moving into phase 3 (all are off ERT, no cardiac events) Accelerating dose escalation for CAR-Treg…
June 8, 2023, 6:09 p.m.
$TELA (L) Telling quote from #JefferiesHealthcare : "When a company hits about $50M on run rate basis, you have to start prepping for $100M and $200M talent pool." Current EV just $200M, pursuing $2B hernia repair opportunity in US Mgmt previously sold LifeCell to Allergan…
June 8, 2023, 2:55 p.m.
